MYND Life Sciences Inc. reported earnings results for the third quarter and nine months ended July 31, 2022. For the third quarter, the company reported net loss was CAD 0.851966 million compared to CAD 0.858455 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.02 a year ago.
For the nine months, net loss was CAD 3.01 million compared to CAD 0.777696 million a year ago. Basic loss per share from continuing operations was CAD 0.06.